Comparative in vitro antibacterial activity of ozenoxacin against Gram-positive clinical isolates

被引：21

作者：

Canton, Rafael ^{[1
,2
,3
]}

Morrissey, Ian ^{[4
]}

Vila, Jordi ^{[3
,5
,6
]}

Tato, Marta ^{[1
,2
,3
]}

Garcia-Castillo, Maria ^{[1
,2
,3
]}

Lopez, Yuly ^{[6
]}

Gargallo-Viola, Domingo ^{[7
]}

Zsolt, Ilonka ^{[7
]}

机构：

[1] Hosp Univ Ramon & Cajal, Serv Microbiol, Madrid, Spain

[2] IRYCIS, Madrid, Spain

[3] REIPI, Madrid, Spain

[4] IHMA Europe Sarl, Monthey, Switzerland

[5] Hosp Clin Barcelona, Ctr Diagnst Biomed, Microbiol Serv, Barcelona, Spain

[6] Inst Global Hlth Barcelona, Barcelona, Spain

[7] Ferrer Int, Dept Med, Barcelona, Spain

来源：

FUTURE MICROBIOLOGY | 2018年 / 13卷 / 06期

关键词：

antibacterial activity; clinical isolates; Gram-positive; MRSA; ozenoxacin; IMPETIGO;

D O I：

10.2217/fmb-2017-0289

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Aim: To compare the in vitro activity of the anti-impetigo agent, ozenoxacin, and other antimicrobial agents against Gram-positive clinical isolates from skin and soft tissue infections. Materials & methods: Isolates were collected in two studies: 1097 isolates from 49 centers during 2009-2010 and 1031 isolates from ten centers during 2014. Minimum inhibitory concentrations were determined for 18 and 11 antimicrobials in these studies, respectively, using standard broth microdilution methods. Isolates were stratified by species and methicillin susceptibility/resistance and/or levofloxacin susceptibility/nonsusceptibility status. Results: Ozenoxacin exhibited high in vitro activity against Staphylococcus aureus and coagulase-negative staphylococci isolates in both studies. Ozenoxacin was also highly active against Streptococcus pyogenes and Streptococcus agalactiae isolates. Conclusion: Ozenoxacin is a potent antimicrobial agent against staphylococci and streptococci.

引用

页码：3 / 19

页数：18

共 17 条

[1]

Albareda N., 2017, J SKIN, V1, pS103, DOI DOI 10.25251/skin.1.supp.102

[2]

[Anonymous], 2011, Performance standards for antimicrobial susceptibility testing: twenty-first informational supplement

[3]

[Anonymous], 2010, CLSI Document M100-S20

[4] Distinguishing between resistance, tolerance and persistence to antibiotic treatment [J].

Brauner, Asher ;

Fridman, Ofer ;

Gefen, Orit ;

Balaban, Nathalie Q. .

NATURE REVIEWS MICROBIOLOGY, 2016, 14 (05) :320-330

[5]

CLSI, 2016, Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria. 3rd ed. CLSI guideline M45

[6]

CLSI, 2021, CLSI supplement M100, V31st, DOI DOI 10.1093/OFID/OFV050

[7]

European Committee on Antimicrobial Susceptibility Testing (EUCAST), 2009, BREAKP TABL INT MICS

[8]

George A, 2003, BRIT J GEN PRACT, V53, P480

[9]

Gropper S, 2014, FUTURE MICROBIOL, V9, P1013, DOI [10.2217/FMB.14.78, 10.2217/fmb.14.78]

[10]

Hartman-Adams H, 2014, AM FAM PHYSICIAN, V90, P229

← 1 2 →